News & Updates

Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.

First-line maintenance therapy with niraparib at an individualized starting dose (ISD) improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, according to results of the phase III PRIME study presented at SGO 2022.

Daily use of aspirin reduces the risk of incident hepatocellular carcinoma (HCC), while the combination of daily aspirin use and statin results in a lower incidence of HCC, which suggests a beneficial interaction, according to a study. In addition, no excess oesophageal variceal haemorrhage (VH) is seen among daily aspirin users compared with nonusers.

SARS-CoV-2 infection during pregnancy or the postpartum period is tied to an increased risk of maternal mortality or serious morbidity due to obstetric complications, a study from the US showed.

When it comes to treating mild chronic hypertension during pregnancy, a strategy of lowering blood pressure (BP) below 140/90 mm Hg is preferrable, as it leads to better pregnancy outcomes without increasing the risk of birthing small-for-gestational-age babies when compared with a strategy of reserving treatment only for severe hypertension, according to the open-label Chronic Hypertension and Pregnancy (CHAP) trial.

Nondiabetic adults with overweight or obesity lost more weight when treated with once-weekly semaglutide than once-daily liraglutide, as demonstrated by results of the phase IIIb STEP* 8 trial.